AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14586376 — intervention group
Group type: COMPARATOR
Intervention: Native oocyte in vitro fertilization
Number of subjects: 64
Study 14586376 — intervention group
Group type: COMPARATOR
Intervention: Frozen/thawed native oocyte cycles
Number of subjects: 64
Study 10790626 — intervention group
Group type: EXPERIMENTAL
Intervention: Bologna procedure
Number of subjects: 47
Study 10790626 — intervention group
Group type: COMPARATOR
Intervention: Ingelman-Sundberg procedure
Number of subjects: 47
Study 9322521 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg daily for 4 weeks)
Number of subjects: 16
Study 9322521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9322521 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone and 6 beta-naltrexol levels
Number of subjects: 16
Study 8485074 — intervention group
Group type: EXPERIMENTAL
Intervention: High-stress interview condition
Number of subjects: 30
Study 8485074 — intervention group
Group type: COMPARATOR
Intervention: Low-stress interview condition
Number of subjects: 30
Study 4056256 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine aerosol, 10 mg in 40% ethanol
Number of subjects: 6
Study 4056256 — intervention group
Group type: COMPARATOR
Intervention: Diluent alone (control)
Number of subjects: 6
Study 29987566 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy with ERAS (LA‐E)
Number of subjects: 108
Study 29987566 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic appendectomy with conventional care (LA‐C)
Number of subjects: 108
Study 29923614 — intervention group
Group type: EXPERIMENTAL
Intervention: C1M (MMP‐generated type I collagen fragment)
Number of subjects: 203
Study 29923614 — intervention group
Group type: EXPERIMENTAL
Intervention: C3M (MMP‐generated type III collagen fragment)
Number of subjects: 203
Study 29923614 — intervention group
Group type: EXPERIMENTAL
Intervention: C4M (MMP‐generated type IV collagen fragment)
Number of subjects: 203
Study 29923614 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO‐C3 (pro‐peptide of type III collagen)
Number of subjects: 203
Study 29923614 — intervention group
Group type: EXPERIMENTAL
Intervention: All collagen fragments
Number of subjects: 203
Study 27311493 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass
Number of subjects: 120
Study 27311493 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle-medical management
Number of subjects: 120
Study 1335388 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-body negative pressure at -10 mmHg
Number of subjects: 15
Study 1335388 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-body negative pressure at -15 mmHg
Number of subjects: 15
Study 1335388 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-up tilt at 30 degrees
Number of subjects: 15
Study 1335388 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-up tilt at 60 degrees
Number of subjects: 15
Study 22747856 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug lymphocyte stimulation test (DLST) performed at Week 1 of adverse reactions
Number of subjects: 0
Study 22747856 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug lymphocyte stimulation test (DLST) performed 2 months after the reaction (Group A)
Number of subjects: 0
Study 22747856 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug lymphocyte stimulation test (DLST) performed >12 months after the reaction (Group B)
Number of subjects: 0
Study 22747856 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 0
Study 19678808 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS (3 Hz)
Number of subjects: 48
Study 19678808 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS (10 Hz)
Number of subjects: 48
Study 19678808 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 48
Study 18768511 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate supplementation
Number of subjects: 0
Study 18768511 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR 677 TT genotype
Number of subjects: 0
Study 18768511 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR 1298 CC genotype
Number of subjects: 0
Study 18768511 — intervention group
Group type: COMPARATOR
Intervention: Control group (wild-type alleles)
Number of subjects: 0
Study 16277550 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin-gemcitabine
Number of subjects: 0
Study 16277550 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine-paclitaxel
Number of subjects: 0
Study 16277550 — intervention group
Group type: COMPARATOR
Intervention: cisplatin-paclitaxel
Number of subjects: 0
Study 12456031 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxy ethyl starch solution (10 ml/kg, 30 minutes)
Number of subjects: 8
Study 12456031 — intervention group
Group type: EXPERIMENTAL
Intervention: FPSA treatment
Number of subjects: 8
Study 10625862 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal phenobarbital
Number of subjects: 49
Study 10625862 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 49
Study 8534744 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis solution at a sodium concentration of 126 mEq/L (low sodium)
Number of subjects: 10
Study 8534744 — intervention group
Group type: COMPARATOR
Intervention: Dialysis solution at a sodium concentration of 132 mEq/L (normal sodium)
Number of subjects: 10
Study 2014078 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioinfusion with warmed saline solution
Number of subjects: 0
Study 2014078 — intervention group
Group type: EXPERIMENTAL
Intervention: Room-temperature saline
Number of subjects: 0
Study 2014078 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 6517242 — intervention group
Group type: EXPERIMENTAL
Intervention: Amezinium methylsulfate 5 mg i.v. given if blood pressure dropped greater than 20 mmHg
Number of subjects: 25
Study 6517242 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study 30892641 — intervention group
Group type: EXPERIMENTAL
Intervention: Online tailored intervention (n = 63)
Number of subjects: 125
Study 30892641 — intervention group
Group type: COMPARATOR
Intervention: Online health education comparison program (n = 62)
Number of subjects: 125
Study 29253244 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic lancet
Number of subjects: 70
Study 29253244 — intervention group
Group type: COMPARATOR
Intervention: Manual lancet
Number of subjects: 70
Study 27261993 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha Yoga
Number of subjects: 88
Study 27261993 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 88
Study 27261993 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga and Exercise
Number of subjects: 88
Study 24238984 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet therapy
Number of subjects: 128
Study 24238984 — intervention group
Group type: COMPARATOR
Intervention: No helmet therapy (control)
Number of subjects: 128
Study 22441566 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab-based treatment
Number of subjects: 54
Study 22441566 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab-based treatment
Number of subjects: 54
Study 20008831 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen 200 mg weekly for 13 weeks
Number of subjects: 21
Study 20008831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 17413113 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable group (5.6 mg beta-carotene/d from green leafy vegetables)
Number of subjects: 280
Study 17413113 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit group (4.8 mg beta-carotene/d from orange or yellow fruit)
Number of subjects: 280
Study 17413113 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinol-rich group (610 microg retinol/d from animal foods and 0.6 mg beta-carotene/d)
Number of subjects: 280
Study 17413113 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.4 mg beta-carotene/d)
Number of subjects: 280
Study 17324333 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib with pegylated liposomal doxorubicin
Number of subjects: 0
Study 17324333 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib without pegylated liposomal doxorubicin
Number of subjects: 0
Study 15672797 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygenator
Number of subjects: 20
Study 15672797 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygenator with venous-arterial shunt
Number of subjects: 20
Study 11115437 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) DPI 400 microg bid
Number of subjects: 44
Study 11115437 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) DPI 800 microg bid
Number of subjects: 44
Study 11115437 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone 10 mg qd
Number of subjects: 44
Study 11115437 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) MDI 800 microg bid
Number of subjects: 44
Study 11115437 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 880 microg bid
Number of subjects: 44
Study 11115437 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate (MF) MDI 400 microg bid
Number of subjects: 44
Study 11115437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 9363727 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (800 mg/day for 12 months)
Number of subjects: 60
Study 9363727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 1543782 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis fluid (2.0 L)
Number of subjects: 11
Study 1543782 — intervention group
Group type: COMPARATOR
Intervention: No peritoneal dialysis fluid
Number of subjects: 11
Study 3991126 — intervention group
Group type: EXPERIMENTAL
Intervention: UV-filtering intraocular lens (IOL)
Number of subjects: 301
Study 3991126 — intervention group
Group type: COMPARATOR
Intervention: Non-UV-filtering intraocular lens (IOL)
Number of subjects: 301
Study 31569208 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related claims made by alcohol marketers and producers
Number of subjects: 0
Study 31569208 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol products marketed as healthier options
Number of subjects: 0
Study 28660740 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-asparaginase (Oncaspar®) 1,000 IU/m²/dose, administered biweekly
Number of subjects: 97
Study 26262196 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app follow-up care
Number of subjects: 0
Study 26262196 — intervention group
Group type: COMPARATOR
Intervention: Conventional in-person follow-up care
Number of subjects: 0
Study 23782504 — intervention group
Group type: EXPERIMENTAL
Intervention: Action 3:30 PA intervention delivered by trained teaching assistants (TAs) including a 25-hour training program, first-aid certification, ongoing support, and 40 one-hour session plans for 20 weeks.
Number of subjects: 20
Study 23782504 — intervention group
Group type: EXPERIMENTAL
Intervention: Action 3:30 PA intervention
Number of subjects: 20
Study 23782504 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative assessments at the end of the intervention period
Number of subjects: 20
Study 23782504 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 20
Study 21171937 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (250 mg of testosterone enanthate every 4 weeks)
Number of subjects: 52
Study 21171937 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 52
Study 18053317 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg
Number of subjects: 975
Study 18053317 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (10-80 mg)
Number of subjects: 975
Study 18053317 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10-80 mg)
Number of subjects: 975
Study 18053317 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe and statins (co-administration)
Number of subjects: 975
Study 18053317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 975
Study 17175680 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored self-management (TSM)
Number of subjects: 335
Study 17175680 — intervention group
Group type: COMPARATOR
Intervention: Computer-aided enhanced usual care (UC)
Number of subjects: 335
Study 17175680 — intervention group
Group type: EXPERIMENTAL
Intervention: TSM
Number of subjects: 335
Study 12625376 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAT exercise programme used daily at home
Number of subjects: 35
Study 12625376 — intervention group
Group type: COMPARATOR
Intervention: Control group (same treatment at school, no DDAT exercise programme)
Number of subjects: 35
Study 12625376 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAT exercise programme
Number of subjects: 35
Study 10741262 — intervention group
Group type: EXPERIMENTAL
Intervention: Oftan-dipivefrin
Number of subjects: 60
Study 10741262 — intervention group
Group type: COMPARATOR
Intervention: Glaucon
Number of subjects: 60
Study 8601979 — intervention group
Group type: EXPERIMENTAL
Intervention: Bair Hugger system (3 hours)
Number of subjects: 0
Study 8601979 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric blanket (4 hours)
Number of subjects: 0
Study 8601979 — intervention group
Group type: COMPARATOR
Intervention: Space blanket
Number of subjects: 0
Study 1528786 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate (CH) 25 mg/kg
Number of subjects: 26
Study 1528786 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate (CH) 50 mg/kg
Number of subjects: 26
Study 1528786 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate (CH) 70 mg/kg
Number of subjects: 26
Study 1528786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 3907791 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine 1 mg/kg
Number of subjects: 40
Study 3907791 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 400 micrograms/kg
Number of subjects: 40
Study 30420478 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B deoxycholate (DAmB)
Number of subjects: 78
Study 29751746 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Factors (HF) indicating current tobacco use
Number of subjects: 1713
Study 26450534 — intervention group
Group type: EXPERIMENTAL
Intervention: Target systolic blood pressure <150 mm Hg
Number of subjects: 73
Study 26450534 — intervention group
Group type: COMPARATOR
Intervention: Target systolic blood pressure <180 mm Hg
Number of subjects: 73
Study 26450534 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 73
Study 24505200 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost/timolol fixed combination (BTFC)
Number of subjects: 58
Study 24505200 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost/timolol fixed combination (LTFC)
Number of subjects: 58
Study 22545212 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS) applied daily on vastus lateralis, vastus medialis, and peroneus longus of both lower extremities.
Number of subjects: 142
Study 22545212 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS)
Number of subjects: 142
Study 22545212 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip strength assessment
Number of subjects: 142
Study 22545212 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EMS)
Number of subjects: 142
Study 21125816 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg entecavir dispersible tablets under fasted conditions
Number of subjects: 12
Study 21125816 — intervention group
Group type: COMPARATOR
Intervention: 1 mg entecavir dispersible tablets under fed conditions
Number of subjects: 12
Study 17692717 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone IR 10 mg
Number of subjects: 331
Study 17692717 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone IR 20 mg
Number of subjects: 331
Study 17692717 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone IR 15 mg
Number of subjects: 331
Study 17692717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study 15119915 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg q.d.
Number of subjects: 512
Study 15119915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 512
Study 11317600 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental health education program (four one-hour lessons)
Number of subjects: 32
Study 9444883 — intervention group
Group type: EXPERIMENTAL
Intervention: Preliminary data showing 9 out of 10 patients improved with drug A
Number of subjects: 165
Study 9444883 — intervention group
Group type: COMPARATOR
Intervention: Preliminary data showing 5 out of 10 patients improved with drug B
Number of subjects: 165
Study 9444883 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher P values presented to subjects
Number of subjects: 165
Study 9444883 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller differences in effectiveness presented to subjects
Number of subjects: 165
Study 9444883 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 165
Study 8278066 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 22
Study 8278066 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 22
Study 3114794 — intervention group
Group type: COMPARATOR
Intervention: Nicotine gum (0 mg)
Number of subjects: 8
Study 3114794 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (2 mg)
Number of subjects: 8
Study 3114794 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (4 mg)
Number of subjects: 8
Study 3114794 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (8 mg)
Number of subjects: 8
Study 30891903 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-by-step teaching method
Number of subjects: 40
Study 30891903 — intervention group
Group type: COMPARATOR
Intervention: All-in-one teaching method (control group)
Number of subjects: 40
Study 29683810 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity physical activity (PA)
Number of subjects: 12
Study 29683810 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical activity (PA)
Number of subjects: 12
Study 29683810 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) preconditioning
Number of subjects: 12
Study 27163830 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17β-estradiol (50μg/day)
Number of subjects: 118
Study 27163830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 27163830 — intervention group
Group type: COMPARATOR
Intervention: Oral CEE (0.45 mg/day)
Number of subjects: 118
Study 25183926 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine with 1ml of isotonic saline (Group L)
Number of subjects: 60
Study 25183926 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine with 1ml of (100 microgram) dexmedetomidine (Group LD)
Number of subjects: 60
Study 22459748 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise program (intermittent walking to nearly maximal claudication pain, 3 days per week)
Number of subjects: 142
Study 22459748 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 142
Study 21143443 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg power
Number of subjects: 116
Study 17647003 — intervention group
Group type: EXPERIMENTAL
Intervention: CCR5 inhibitor SCH351125
Number of subjects: 32
Study 17647003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 15833572 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-form survey (n=137)
Number of subjects: 280
Study 15833572 — intervention group
Group type: COMPARATOR
Intervention: Paper-form survey (n=143)
Number of subjects: 280
Study 12199726 — intervention group
Group type: EXPERIMENTAL
Intervention: PNESs alone (n=50)
Number of subjects: 187
Study 12199726 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n=50)
Number of subjects: 187
Study 12199726 — intervention group
Group type: EXPERIMENTAL
Intervention: PNESs alone (n=130)
Number of subjects: 187
Study 12199726 — intervention group
Group type: EXPERIMENTAL
Intervention: PNES+E (n=57)
Number of subjects: 187
Study 12199726 — intervention group
Group type: EXPERIMENTAL
Intervention: PNES-only (n=130)
Number of subjects: 187
Study 12199726 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PNESs and controls)
Number of subjects: 187
Study 10480473 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan plus HCTZ (various combinations)
Number of subjects: 683
Study 10480473 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan monotherapy (0, 37.5, 100, and 300 mg)
Number of subjects: 683
Study 10480473 — intervention group
Group type: EXPERIMENTAL
Intervention: HCTZ monotherapy (0, 6.25, 12.5, and 25 mg)
Number of subjects: 683
Study 10480473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 683
Study 8836471 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual words
Number of subjects: 0
Study 8836471 — intervention group
Group type: EXPERIMENTAL
Intervention: Romantic words
Number of subjects: 0
Study 8836471 — intervention group
Group type: COMPARATOR
Intervention: Word familiarity
Number of subjects: 0
Study 8836471 — intervention group
Group type: COMPARATOR
Intervention: Word emotionality
Number of subjects: 0
Study 8836471 — intervention group
Group type: COMPARATOR
Intervention: Word acceptability
Number of subjects: 0
Study 1747725 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose alpha-2b interferon (10 x 10(6) IU)
Number of subjects: 44
Study 1747725 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose alpha-2b interferon (100 x 10(6) IU)
Number of subjects: 44
Study 1747725 — intervention group
Group type: COMPARATOR
Intervention: Ethoglucid
Number of subjects: 44
Study 6758093 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor XIII (Fibrogammine)
Number of subjects: 25
Study 6758093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 30278459 — intervention group
Group type: EXPERIMENTAL
Intervention: B&B Bubbler©
Number of subjects: 43
Study 30278459 — intervention group
Group type: COMPARATOR
Intervention: BabiPlus©
Number of subjects: 43